Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trialSabine C A Meijvis, Douwe H. Biesma, Hans A Hardeman et al.|The Lancet|2011Cited by 372
Pharmacokinetics of oral <i>vs</i>. intravenous dexamethasone in patients hospitalized with community‐acquired pneumoniaSimone M.C. Spoorenberg, E.M.W. van de Garde, Vera H.M. Deneer et al.|British Journal of Clinical Pharmacology|2013Cited by 95
Statins and prevention of infections: systematic review and meta-analysis of data from large randomised placebo controlled trialsH. L. van den Hoek, E.M.W. van de Garde, Willem Jan W. Bos et al.|BMJ|2011Cited by 75
Addition of Vitamin D Status to Prognostic Scores Improves the Prediction of Outcome in Community-Acquired PneumoniaHilde H.F. Remmelts, Ger T. Rijkers, E.M.W. van de Garde et al.|Clinical Infectious Diseases|2012Cited by 74
Microbial aetiology, outcomes, and costs of hospitalisation for community-acquired pneumonia; an observational analysisSimone M.C. Spoorenberg, E.M.W. van de Garde, Willem Jan W. Bos et al.|BMC Infectious Diseases|2014Cited by 58